What is the recommended follow-up interval for a patient with a normal Papanicolaou (PAP) smear but a positive Human Papillomavirus (HPV) test?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 22, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Repeat Testing Interval for Normal PAP with Positive HPV

For a patient with a normal PAP smear but positive high-risk HPV test, repeat HPV testing with or without concurrent PAP should be performed in 1 year. 1

Management Algorithm

Initial Assessment

  • If HPV genotyping shows HPV 16 or 18: Proceed directly to colposcopy regardless of normal cytology, as these genotypes carry the highest risk (17% and 14% respectively for CIN 3+) 1, 2
  • If HPV type is non-16/18 high-risk: Return in 1 year for repeat testing 1

One-Year Follow-Up Testing

The preferred approach is HPV testing with or without concurrent PAP (cotesting), rather than cytology alone, as HPV testing is less likely to miss disease 1

At the 1-year follow-up visit:

  • If both tests are negative: Return to routine 3-year screening intervals 1, 3
  • If HPV remains positive OR cytology is abnormal: Refer for colposcopy 1
  • If HPV positive but cytology normal: Repeat testing in another year or consider colposcopy 1, 3

Two Consecutive Positive HPV Tests

  • Colposcopy is always recommended for two consecutive HPV-positive tests, regardless of cytology results 1

Key Evidence Supporting 1-Year Interval

The 2021 CDC STI Treatment Guidelines and 2019 ASCCP Risk-Based Management Consensus Guidelines both specify that women with normal cytology but positive high-risk HPV should be retested at 1 year 1. This represents a change from older 2012 guidelines that recommended immediate colposcopy for all HPV-positive results 1.

The rationale for 1-year surveillance rather than immediate colposcopy includes:

  • Risk stratification shows that a single HPV-positive result with normal cytology in women with recent negative screening history (within 5 years) carries lower immediate risk for CIN 3+ 1
  • Many HPV infections clear spontaneously within 12-24 months, particularly in younger women 1
  • Persistent HPV positivity at 1 year significantly elevates risk and warrants colposcopy 1

Critical Pitfalls to Avoid

Do not extend the screening interval beyond 1 year for initial follow-up of HPV-positive, cytology-negative results 3. The first follow-up must occur at 1 year to ensure appropriate surveillance.

Do not use cytology alone for follow-up testing. HPV testing or cotesting is preferred because it has higher sensitivity (88-90%) for detecting high-grade lesions compared to cytology alone (76.2%) 2, 4

Do not assume this represents routine screening. A positive HPV test, even with normal cytology, places the patient in a surveillance protocol rather than routine screening 1. She cannot return to 3-year intervals until demonstrating negative results.

For women over age 30: HPV positivity is more concerning and less likely to represent transient infection, with higher risk of underlying significant disease 2. The 1-year follow-up is particularly important in this age group.

Special Consideration for Previous Screening History

If the patient had a negative HPV test or cotest within the previous 5 years before this current positive result, the risk is lower and 1-year follow-up is appropriate 1. However, if there is no recent negative screening history, some guidelines suggest colposcopy may be considered, though 1-year follow-up remains acceptable 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Abnormal Cervical Screening Results

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Non-High-Risk HPV Positive Status

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the recommended follow-up interval for Pap screening with Human Papillomavirus (HPV) testing for a 24-year-old patient with a history of positive HPV (not types 16 or 18) and current normal Pap smear and negative HPV test?
How often should a 24-year-old female with no high-risk factors have a Pap (Papanicolau) smear?
What is the recommended management for a 32-year-old patient with an abnormal Pap (Papanicolau) smear showing Atypical Squamous Cells of Undetermined Significance (ASCUS) and a negative Human Papillomavirus (HPV) test?
What is the recommended management for a 41-year-old female with a PAP (Pap smear) result showing Atypical Squamous Cells of Undetermined Significance (ASCUS) and a Human Papillomavirus (HPV) negative status?
What is the next step for a 59-year-old female with a Pap result showing Atypical Squamous Cells of Undetermined Significance (ASC-US) and a negative Human Papillomavirus (HPV) test?
What is the recommended management for a patient with type 1 Hepatorenal Syndrome (HRS) characterized by rapid deterioration of renal function?
Can chronic urinary retention discomfort sensation related to pelvic tightness in an older adult with a history of complex anorectal conditions or multiple surgeries be treated?
How do the ROME IV criteria apply to a patient with constipation, watery stools, and right lower quadrant pain, and what treatment options are available if they are diagnosed with irritable bowel syndrome (IBS)?
What does an elevated Blood Urea Nitrogen (BUN) and creatinine ratio indicate in a patient with type 2 diabetes mellitus and impaired renal function?
What is the estimated lifetime risk of breast cancer for a 52-year-old female with a family history of breast cancer, including a sister diagnosed at 54, a maternal aunt in her 50s, and a maternal grandmother in her 50s?
What are the target tacrolimus (immunosuppressive medication) levels in a lung transplant patient?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.